Success in 2017 often depended on identifying specific catalysts within high-risk industries:
: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally. high risk stocks to buy 2017
: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate. Success in 2017 often depended on identifying specific
The following stocks represented some of the most successful speculative plays for the year: high risk stocks to buy 2017